These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 15981681)
1. Outcome of ablation of thyroid remnants with 100 mCi (3.7 GBq) iodine-131 in patients with thyroid cancer. Rosário PW; Barroso AL; Rezende LL; Padrão EL; Fagundes TA; Reis JS; Purisch S Ann Nucl Med; 2005 May; 19(3):247-50. PubMed ID: 15981681 [TBL] [Abstract][Full Text] [Related]
2. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence. Rosário PW; Calsolari MR Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207 [TBL] [Abstract][Full Text] [Related]
3. Radioiodine remnant ablation in low-risk differentiated thyroid cancer. Saengsuda Y J Med Assoc Thai; 2013 May; 96(5):614-24. PubMed ID: 23745318 [TBL] [Abstract][Full Text] [Related]
4. Ablative treatment of thyroid cancer with high doses of 131I without pre-therapy scanning. Rosário PW; Barroso AL; Rezende LL; Padrão EL; Borges MA; Fagundes TA; Purisch S Nucl Med Commun; 2005 Feb; 26(2):129-32. PubMed ID: 15657505 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake. Rosário PW; Reis JS; Barroso AL; Rezende LL; Padrão EL; Fagundes TA Nucl Med Commun; 2004 Nov; 25(11):1077-81. PubMed ID: 15577584 [TBL] [Abstract][Full Text] [Related]
6. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates. Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064 [TBL] [Abstract][Full Text] [Related]
7. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? Mazzaferri EL; Kloos RT J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270 [TBL] [Abstract][Full Text] [Related]
8. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up. Ahtiainen V; Vaalavirta L; Tenhunen M; Joensuu H; Mäenpää H Acta Oncol; 2020 Sep; 59(9):1064-1071. PubMed ID: 32603613 [No Abstract] [Full Text] [Related]
9. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? Cailleux AF; Baudin E; Travagli JP; Ricard M; Schlumberger M J Clin Endocrinol Metab; 2000 Jan; 85(1):175-8. PubMed ID: 10634383 [TBL] [Abstract][Full Text] [Related]
10. Short-term effectiveness of low-dose radioiodune ablative treatment of thyroid remnants after thyroidectomy for differentiated thyroid cancer. Vermiglio F; Violi MA; Finocchiaro MD; Baldari S; Castagna MG; Moleti M; Mattina F; Pio Lo Presti V; Bonanno N; Trimarchi F Thyroid; 1999 Apr; 9(4):387-91. PubMed ID: 10319946 [TBL] [Abstract][Full Text] [Related]
11. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension. Han JM; Kim WG; Kim TY; Jeon MJ; Ryu JS; Song DE; Hong SJ; Shong YK; Kim WB Thyroid; 2014 May; 24(5):820-5. PubMed ID: 24328997 [TBL] [Abstract][Full Text] [Related]
12. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. Lees W; Mansberg R; Roberts J; Towson J; Chua E; Turtle J Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1421-7. PubMed ID: 12397458 [TBL] [Abstract][Full Text] [Related]
13. [Follow-up of high-risk patients with differentiated thyroid cancer without persistent disease after initial therapy]. do Rosário PW; Borges MA; Alves MF; Purisch S; Padrão EL; Rezende LL; Barroso AL Arq Bras Endocrinol Metabol; 2006 Oct; 50(5):909-13. PubMed ID: 17160215 [TBL] [Abstract][Full Text] [Related]
14. Longer-term recurrence rate after low versus high dose radioiodine ablation for differentiated thyroid Cancer in low and intermediate risk patients: a meta-analysis. Vardarli I; Weidemann F; Aboukoura M; Herrmann K; Binse I; Görges R BMC Cancer; 2020 Jun; 20(1):550. PubMed ID: 32539683 [TBL] [Abstract][Full Text] [Related]
15. Treatment for microcarcinoma of the thyroid--clinical experience. Küçük NO; Tari P; Tokmak E; Aras G Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573 [TBL] [Abstract][Full Text] [Related]
16. Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Chianelli M; Todino V; Graziano FM; Panunzi C; Pace D; Guglielmi R; Signore A; Papini E Eur J Endocrinol; 2009 Mar; 160(3):431-6. PubMed ID: 19074463 [TBL] [Abstract][Full Text] [Related]
17. Prescribing 131Iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay. Hodgson DC; Brierley JD; Tsang RW; Panzarella T Radiother Oncol; 1998 Jun; 47(3):325-30. PubMed ID: 9681898 [TBL] [Abstract][Full Text] [Related]
18. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma. Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785 [TBL] [Abstract][Full Text] [Related]
19. Recombinant human thyroid stimulating hormone in thyroid remnant ablation with 1.1 GBq 131iodine in low-risk patients. Rosario PW; Xavier AC Am J Clin Oncol; 2012 Apr; 35(2):101-4. PubMed ID: 21297429 [TBL] [Abstract][Full Text] [Related]
20. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer. Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]